Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses multiple molecular pathways. The first-generation antifibrotics pirfenidone and nintedanib, approved more than 10 years ago, have been shown to reduce the rate of progression, increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonella, Francesco, Spagnolo, Paolo, Ryerson, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693523/
https://www.ncbi.nlm.nih.gov/pubmed/37882943
http://dx.doi.org/10.1007/s40265-023-01950-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693523/
https://www.ncbi.nlm.nih.gov/pubmed/37882943
http://dx.doi.org/10.1007/s40265-023-01950-0

Ejemplares similares